12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      C-Reactive Protein in Atherothrombosis and Angiogenesis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          C-reactive protein (CRP) is a short pentraxin mainly found as a pentamer in the circulation, or as non-soluble monomers CRP (mCRP) in tissues, exerting different functions. This review is focused on discussing the role of CRP in cardiovascular disease, including recent advances on the implication of CRP and its forms specifically on the pathogenesis of atherothrombosis and angiogenesis. Besides its role in the humoral innate immune response, CRP contributes to cardiovascular disease progression by recognizing and binding multiple intrinsic ligands. mCRP is not present in the healthy vessel wall but it becomes detectable in the early stages of atherogenesis and accumulates during the progression of atherosclerosis. CRP inhibits endothelial nitric oxide production and contributes to plaque instability by increasing endothelial cell adhesion molecules expression, by promoting monocyte recruitment into the atheromatous plaque and by enzymatically binding to modified low-density lipoprotein. CRP also contributes to thrombosis, but depending on its form it elicits different actions. Pentameric CRP has no involvement in thrombogenesis, whereas mCRP induces platelet activation and thrombus growth. In addition, mCRP has apparently contradictory pro-angiogenic and anti-angiogenic effects determining tissue remodeling in the atherosclerotic plaque and in infarcted tissues. Overall, CRP contributes to cardiovascular disease by several mechanisms that deserve an in-depth analysis.

          Related collections

          Most cited references65

          • Record: found
          • Abstract: not found
          • Article: not found

          C-reactive protein: a critical update.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.

            The incremental usefulness of adding multiple biomarkers from different disease pathways for predicting the risk of death from cardiovascular causes has not, to our knowledge, been evaluated among the elderly. We used data from the Uppsala Longitudinal Study of Adult Men (ULSAM), a community-based cohort of elderly men, to investigate whether a combination of biomarkers that reflect myocardial cell damage, left ventricular dysfunction, renal failure, and inflammation (troponin I, N-terminal pro-brain natriuretic peptide, cystatin C, and C-reactive protein, respectively) improved the risk stratification of a person beyond an assessment that was based on the established risk factors for cardiovascular disease (age, systolic blood pressure, use or nonuse of antihypertensive treatment, total cholesterol, high-density lipoprotein cholesterol, use or nonuse of lipid-lowering treatment, presence or absence of diabetes, smoking status, and body-mass index). During follow-up (median, 10.0 years), 315 of the 1135 participants in our study (mean age, 71 years at baseline) died; 136 deaths were the result of cardiovascular disease. In Cox proportional-hazards models adjusted for established risk factors, all of the biomarkers significantly predicted the risk of death from cardiovascular causes. The C statistic increased significantly when the four biomarkers were incorporated into a model with established risk factors, both in the whole cohort (C statistic with biomarkers vs. without biomarkers, 0.766 vs. 0.664; P<0.001) and in the group of 661 participants who did not have cardiovascular disease at baseline (0.748 vs. 0.688, P=0.03). The improvement in risk assessment remained strong when it was estimated by other statistical measures of model discrimination, calibration, and global fit. Our data suggest that in elderly men with or without prevalent cardiovascular disease, the simultaneous addition of several biomarkers of cardiovascular and renal abnormalities substantially improves the risk stratification for death from cardiovascular causes beyond that of a model that is based only on established risk factors. Copyright 2008 Massachusetts Medical Society.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis.

              Inconsistent findings have been reported on the association between high-sensitivity C-reactive protein (hs-CRP) and mortality risk. The objective of this meta-analysis was to investigate the association of elevated baseline hs-CRP levels with all-cause, cardiovascular, and cancer mortality risk in the general population.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                02 March 2018
                2018
                : 9
                : 430
                Affiliations
                [1] 1Cardiovascular Science Institute – ICCC, IIB-Sant Pau, Hospital de Sant Pau , Barcelona, Spain
                [2] 2CiberCV, Institute Carlos III , Madrid, Spain
                [3] 3School of Healthcare Science, Manchester Metropolitan University , Manchester, United Kingdom
                Author notes

                Edited by: Olivier Garraud, Institut National de la Transfusion Sanguine, France

                Reviewed by: Beate E. Kehrel, University Hospital Muenster, Germany; Hugo Caire Castro-Faria-Neto, Fundação Oswaldo Cruz (Fiocruz), Brazil

                *Correspondence: Lina Badimon, lbadimon@ 123456santpau.cat

                Specialty section: This article was submitted to Inflammation, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2018.00430
                5840191
                29552019
                cf1e55e7-12c1-4835-86d4-ecb0b85ee92c
                Copyright © 2018 Badimon, Peña, Arderiu, Padró, Slevin, Vilahur and Chiva-Blanch.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 21 November 2017
                : 16 February 2018
                Page count
                Figures: 2, Tables: 0, Equations: 0, References: 72, Pages: 7, Words: 5840
                Funding
                Funded by: Ministerio de Economía y Competitividad 10.13039/501100003329
                Award ID: IJCI-2015-26358, SAF2016-76819-R
                Funded by: Instituto de Salud Carlos III 10.13039/501100004587
                Award ID: TERCEL - RD16/0011/0018, CIBERCV CB16/11/0041
                Funded by: European Regional Development Fund 10.13039/501100008530
                Categories
                Immunology
                Mini Review

                Immunology
                c-reactive protein,pentameric c-reactive protein,monomeric c-reactive protein,atherosclerosis,thrombosis,angiogenesis,ischemic heart disease,cardiovascular disease

                Comments

                Comment on this article